Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Good Sign:
Beneish M-Score -2.69 no higher than -1.78, which implies that the company is unlikely to be a manipulator.
The historical rank and industry rank for Sartorius Stedim Biotech's Beneish M-Score or its related term are showing as below:
MEX:DIM N'
s Beneish M-Score Range Over the Past 10 Years
Min: -3.03 Med: -2.51 Max: -1.39
Current: -2.69
During the past 13 years, the highest Beneish M-Score of Sartorius Stedim Biotech was -1.39. The lowest was -3.03. And the median was -2.51.
Sartorius Stedim Biotech Beneish M-Score Related Terms
Sartorius Stedim Biotech Beneish M-Score Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:DIM N vs ISRG, BDX, MDLN: Beneish M-Score Comparison
For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius Stedim Biotech Beneish M-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Sartorius Stedim Biotech's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Sartorius Stedim Biotech for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 0.9683
+
0.528 * 0.9953
+
0.404 * 1.0382
+
0.892 * 0.99
+
0.115 * 0.9902
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 0.9516
+
4.679 * -0.065607
-
0.327 * 0.9033
=
-2.77
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(6829.098 / (6829.098 + 42436.282))
/
(6754.557 / (6754.557 + 41497.662))
=
0.138619
/
0.139984
=
0.9902
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(6085.706 - 0
-
16527.777)
/
159161.817
=
-0.065607
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Sartorius Stedim Biotech has a M-score of -2.77 suggests that the company is unlikely to be a manipulator.
Sartorius Stedim Biotech (MEX:DIM N) has a Beneish M-Score of -2.69 as of Jul. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sartorius Stedim Biotech and its competitors. According to the industry distribution chart, Sartorius Stedim Biotech ranks #248 out of 762 companies in the Medical Devices & Instruments industry, placing it in the top 32.5%.
Is Sartorius Stedim Biotech's Beneish M-Score too high?
Sartorius Stedim Biotech's current Beneish M-Score is -2.69. Based on the distribution chart, Sartorius Stedim Biotech ranks #248 out of 762 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sartorius Stedim Biotech has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Beneish M-Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius Stedim Biotech ranks #248 out of 762 companies for Beneish M-Score. This puts Sartorius Stedim Biotech in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sartorius Stedim Biotech and its competitors. Sartorius Stedim Biotech's current Beneish M-Score is -2.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Sartorius Stedim Biotech (MEX:DIM N) has a current Beneish M-Score of -2.69. The stock's GF Value™ is MXN5,277.61, compared to a current price of MXN4,374.26 — trading 17.1% below its estimated fair value. The current Beneish M-Score is -2.69. Sartorius Stedim Biotech's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Sartorius Stedim Biotech (MEX:DIM N), the current Beneish M-Score is -2.69 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (MEX:DIM N) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of MXN4,374.26 is trading 17.1% below its estimated GF Value™ of MXN5,277.61.
Key valuation signals for MEX:DIM N:
Beneish M-Score: -2.69
GF Value™: MXN5,277.61 vs. price of MXN4,374.26 (17.1% below fair value)
No single metric tells the full story. See the MEX:DIM N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
91GF Score
Get the complete analysis for MEX:DIM N
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:DIM N has been successfully added to your 
